Evidence map›Paper›PMID 39974545›Full record

ArticleSurgical case reports2025

Intrahepatic Cholangiocarcinoma with

Yoshifumi Morita, Koki Oda, Akio Matsumoto, Shinya Ida, Ryo Kitajima, Satoru Furuhashi, Makoto Takeda, Hirotoshi Kikuchi, Yoshihiro Hiramatsu, Jun Ito and 7 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Surgical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Yoshifumi MoritaDepartment of Surgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.
Koki OdaDepartment of Surgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.
Akio MatsumotoDepartment of Surgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.
Shinya IdaDepartment of Surgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.
Ryo KitajimaDepartment of Surgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.
Satoru FuruhashiDepartment of Surgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.
Makoto TakedaDepartment of Surgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.
Hirotoshi KikuchiDepartment of Surgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.
Yoshihiro HiramatsuDepartment of Surgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.
Jun ItoHepatology Division, Department of Internal Medicine II, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.
Takeshi ChidaHepatology Division, Department of Internal Medicine II, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.
Hidenao NoritakeHepatology Division, Department of Internal Medicine II, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.
Kazuhito KawataHepatology Division, Department of Internal Medicine II, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.
Yuka NagakuraDepartment of Pathology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.
Mana GotoDepartment of Pathology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.
Satoshi BabaDepartment of Pathology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.
Hiroya TakeuchiDepartment of Surgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionIntrahepatic cholangiocarcinoma (ICC) is a highly malignant cancer for which surgery is the only curative treatment. The prognosis of ICC is extremely poor, especially in cases of lymph node metastasis (LNM), owing to the high postoperative recurrence rate. Herein, we present a case of advanced ICC with a breast cancer susceptibility gene-2 ( CASE PRESENTATION: A 52-year-old woman was referred to our hospital and was subsequently diagnosed with bilateral breast cancer. Computed tomography (CT) and magnetic resonance imaging incidentally detected a liver tumor in the hilar region and lymph node enlargement in the hepatoduodenal ligament. A 19 mm tumor was observed in the area surrounded by the right and left branches of the portal vein and an abnormal portal branch of segment 7. Positron emission tomography-CT showed fluorodeoxyglucose uptake in the liver tumor, hepatoduodenal ligament lymph nodes, and bilateral breasts. A tumor biopsy showed a papillary tumor, and ICC was suspected. As ICC with LNM has a poor prognosis, neoadjuvant chemotherapy was planned. Genetic testing using a blood sample revealed a

conclusionsWe encountered a patient with advanced ICC with a

Indexed as

BRCAcomplete responseGCS therapyintrahepatic cholangiocarcinomaneoadjuvant

Identifiers

PMID39974545
PMCPMC11835984

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.